Johnson & Johnson Stock (NYSE:JNJ)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$161.17

52W Range

$143.13 - $168.85

50D Avg

$162.41

200D Avg

$155.78

Market Cap

$386.36B

Avg Vol (3M)

$6.63M

Beta

0.52

Div Yield

$4.96 (3.03%)

JNJ Company Profile


Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

131,900

IPO Date

Jan 02, 1943

Website

JNJ Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Jan 23Jan 22
MedTech$30.40B$27.43B-
Pharmaceutical-$52.56B-
Consumer-$14.95B$14.63B

Fiscal year ends in Dec 23 | Currency in USD

JNJ Financial Summary


Dec 23Jan 23Jan 22
Revenue$85.15B$94.94B$93.78B
Operating Income$21.85B$23.92B$24.42B
Net Income$14.17B$17.94B$20.88B
EBITDA$29.34B$24.02B$25.70B
Basic EPS$5.59$6.83$7.93
Diluted EPS$5.53$6.73$7.81

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 17, 24 | 12:00 AM
Q1 24Apr 16, 24 | 12:19 PM
Q4 23Jan 23, 24 | 1:14 PM

Peer Comparison


TickerCompany
LLYEli Lilly and Company
ABBVAbbVie Inc.
MRKMerck & Co., Inc.
AMGNAmgen Inc.
BMYBristol-Myers Squibb Company
GILDGilead Sciences, Inc.
PFEPfizer Inc.